Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEAPOD: Apremilast in Children With Active Juvenile Psoriatic Arthritis
2019-002788-88Phase 3Active
- Sponsor
- Amgen
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in juvenile psoriatic arthritis (JPsA) and systemic juvenile idiopathic arthritis (SJIA) comparing Apremilast with Placebo (2 arms). Primary endpoint: ACR Pedi 30 response. Started Nov 2020; status: active.
02
Drugs
apremilast
03
Conditions
juvenile psoriatic arthritis (JPsA)systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on 2019-002788-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002788-88.